The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used for the treatment of hematologic cancers and disorders. However, graft-versus-host disease (GVHD) in which the donor immune cells attack the genetically-disparate recipient is a significant cause of morbidity. Acute GVHD is an in...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Gut Microbes |
Online Access: | http://dx.doi.org/10.1080/19490976.2021.1966262 |
id |
doaj-7c309182d1044d8fb600e5516c7f12aa |
---|---|
record_format |
Article |
spelling |
doaj-7c309182d1044d8fb600e5516c7f12aa2021-09-06T14:06:26ZengTaylor & Francis GroupGut Microbes1949-09761949-09842021-01-0113110.1080/19490976.2021.19662621966262The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantationLam T. Khuat0Maneesh Dave1William J. Murphy2School of Medicine, University of CaliforniaSchool of Medicine, University of CaliforniaSchool of Medicine, University of CaliforniaAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is used for the treatment of hematologic cancers and disorders. However, graft-versus-host disease (GVHD) in which the donor immune cells attack the genetically-disparate recipient is a significant cause of morbidity. Acute GVHD is an inflammatory condition and the gastrointestinal system is a major organ affected but is also tied to beneficial graft-versus-tumor (GVT) effects. There is increasing interest on the role of the microbiome on immune function as well as on cancer progression and immunotherapy outcomes. However, there are still significant unanswered questions on the role the microbiome plays in GVHD progression or how to exploit the microbiome in GVHD prevention or treatment. In this review, concepts of HSCT with the focus on GVHD pathogenesis as well as issues in preclinical models used to study GVHD will be discussed with an emphasis on the impact of the microbiome. Factors affecting the microbiome and GVHD outcome such as obesity are also examined. The bridging of preclinical models and clinical outcomes in relation to the role of the microbiome will also be discussed along with possibilities for therapeutic exploitation.http://dx.doi.org/10.1080/19490976.2021.1966262 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lam T. Khuat Maneesh Dave William J. Murphy |
spellingShingle |
Lam T. Khuat Maneesh Dave William J. Murphy The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation Gut Microbes |
author_facet |
Lam T. Khuat Maneesh Dave William J. Murphy |
author_sort |
Lam T. Khuat |
title |
The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation |
title_short |
The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation |
title_full |
The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation |
title_fullStr |
The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation |
title_full_unstemmed |
The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation |
title_sort |
emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation |
publisher |
Taylor & Francis Group |
series |
Gut Microbes |
issn |
1949-0976 1949-0984 |
publishDate |
2021-01-01 |
description |
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used for the treatment of hematologic cancers and disorders. However, graft-versus-host disease (GVHD) in which the donor immune cells attack the genetically-disparate recipient is a significant cause of morbidity. Acute GVHD is an inflammatory condition and the gastrointestinal system is a major organ affected but is also tied to beneficial graft-versus-tumor (GVT) effects. There is increasing interest on the role of the microbiome on immune function as well as on cancer progression and immunotherapy outcomes. However, there are still significant unanswered questions on the role the microbiome plays in GVHD progression or how to exploit the microbiome in GVHD prevention or treatment. In this review, concepts of HSCT with the focus on GVHD pathogenesis as well as issues in preclinical models used to study GVHD will be discussed with an emphasis on the impact of the microbiome. Factors affecting the microbiome and GVHD outcome such as obesity are also examined. The bridging of preclinical models and clinical outcomes in relation to the role of the microbiome will also be discussed along with possibilities for therapeutic exploitation. |
url |
http://dx.doi.org/10.1080/19490976.2021.1966262 |
work_keys_str_mv |
AT lamtkhuat theemergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation AT maneeshdave theemergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation AT williamjmurphy theemergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation AT lamtkhuat emergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation AT maneeshdave emergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation AT williamjmurphy emergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation |
_version_ |
1717779289756139520 |